PARIS – Clinicians were the target audience during the first day of presentations at the International Liver Congress (ILC), hosted by the European Association for the Study of the Liver (EASL). On Wednesday morning, EASL interactive research think tanks – a new format at this year's ILC – examined emerging studies in eight areas of importance to treating physicians. Topics ranged from identification of targets and pharmacotherapy in nonalcoholic steatohepatitis (NASH) to options and trends in managing advanced hepatocellular carcinoma (HCC), new directions in treating liver disease and the integration of care for HCV infection and substance use among people who use drugs.